Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19
Erica Villa, Rosina Maria Critelli, Simone Lasagni, Alessandra Melegari, A Curatolo, Ciro Celsa, Dante Romagnoli, Gabriele Melegari, Alessandra Pivetti, Lorenza Di Marco, Federico Casari, Dimitriy Arioli, F Turrini, Valentina Zuccaro, Irene Cassaniti, Mattia Riefolo, Elena De Santis, Veronica Bernabucci, Marcello Bianchini, Barbara Lei, Nicola De Maria, Lucia Carulli, Filippo Schepis, Chiara Gozzi, Silvio Malaguti, Mariagrazia Del Buono, Lucio Brugioni, Pietro Torricelli, Tommaso Trenti, Giovanni Pinelli, Elisabetta Bertellini, Raffaele Bruno, Calogero Cammà, Antonia D’Errico
Abstract
This study examined the association between dynamic angiopoietin-2 assessment and COVID-19 short- and long-term clinical course. We included consecutive hospitalized patients from 1 February to 31 May 2020 with laboratory-confirmed COVID-19 from 2 Italian tertiary referral centers (derivation cohort, n = 187 patients; validation cohort, n = 62 patients). Serum biomarker levels were measured by sandwich enzyme-linked immunosorbent assay. Lung tissue from 9 patients was stained for angiopoietin-2, Tie2, CD68, and CD34. Cox model was used to identify risk factors for mortality and nonresolving pulmonary condition. Area under the receiver operating characteristic curve (AUROC) was used to assess the accuracy of 3- and 10-day angiopoietin-2 for in-hospital mortality and nonresolving pulmonary condition, respectively. Three-day angiopoietin-2 increase of at least twofold from baseline was significantly associated with in-hospital mortality by multivariate analysis (hazard ratio [HR], 6.69; 95% confidence interval [CI], 1.85-24.19; P = .004) with AUROC = 0.845 (95% CI, 0.725-0.940). Ten-day angiopoietin-2 of at least twofold from baseline was instead significantly associated with nonresolving pulmonary condition by multivariate analysis (HR, 5.33; 95% CI, 1.34-11.77; P ≤ .0001) with AUROC = 0.969 (95% CI, 0.919-1.000). Patients with persistent elevation of 10-day angiopoietin-2 levels showed severe reticular interstitial thickening and fibrous changes on follow-up computed tomography scans. Angiopoietin-2 and Tie2 were diffusely colocalized in small-vessel endothelia and alveolar new vessels and macrophages. Angiopoietin-2 course is strongly associated with COVID-19 in-hospital mortality and nonresolving pulmonary condition. Angiopoietin-2 may be an early and useful predictor of COVID-19 clinical course, and it could be a relevant part of disease pathogenesis. Angiopoietin-2 blockade may be a COVID-19 treatment option.